KFAS
PRQR icon

Keating Financial Advisory Services’s ProQR Therapeutics PRQR Stock Holding History

Keating Financial Advisory Services’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.4K Buy
47,552
+27,000
+131% +$44.5K 0.01% 531
2026
Q1 		$33.3K Buy
20,552
+552
+3% +$905 0.01% 742
2025
Q4 		$40.4K Buy
+20,000
New +$46.7K 0.01% 703

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Keating Financial Advisory Services's PRQR Position: Q2 2026 in Review

Keating Financial Advisory Services increased its ProQR Therapeutics (PRQR) stake by 131% in Q2 2026, buying an estimated $44.5K and bringing the position to 47,552 shares worth $88.4K. The position accounts for 0.01% of the portfolio, ranked #531.

Keating Financial Advisory Services first reported a position in PRQR in Q4 2025 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold PRQR as of Q2 2026.

  • Keating Financial Advisory Services held 47,552 shares of ProQR Therapeutics worth $88.4K as of Q2 2026.
  • Keating Financial Advisory Services bought 27,000 ProQR Therapeutics shares in Q2 2026, an estimated $44.5K.
  • ProQR Therapeutics made up 0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #531 holding.
  • Keating Financial Advisory Services first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.